ANTX Overview

Funding and Collaboration: AN2 Therapeutics has received a third year of funding from the Gates Foundation to support its collaboration with GSK in developing new therapies for tuberculosis (TB), a significant global health issue affecting over a quarter of the world's population.

Boron Chemistry Platform: The company utilizes a unique boron chemistry platform for drug discovery, which allows for the design of compounds targeting novel mechanisms, potentially leading to breakthroughs in treating infectious diseases and oncology.

Commitment to TB Treatment: Both AN2 and GSK emphasize their commitment to addressing the urgent needs of TB patients, particularly in lower-income countries, through innovative scientific approaches and strong partnerships.

Forward-Looking Statements: The announcement includes forward-looking statements regarding the potential success of their collaboration and the development of new therapeutics, acknowledging the inherent risks and uncertainties involved in drug discovery and regulatory processes.

Collaboration for Chagas Disease Treatment: AN2 Therapeutics and DNDi are collaborating to advance the clinical development of AN2-502998, an oral drug candidate with potential to cure chronic Chagas disease, which affects millions globally.

Clinical Trial Plans: Startup activities for a Phase 1 human study of AN2-502998 are underway, with a Phase 2 study expected to begin in 2026, aiming to provide a safer and more effective treatment option for Chagas disease.

Study Findings: A 200-patient observational study on acute melioidosis revealed a high mortality rate of nearly 40% among confirmed cases despite standard treatments, emphasizing the urgent need for more effective therapies and early detection.

Future Plans: AN2 Therapeutics plans to initiate a Phase 2 proof-of-concept trial for epetraborole, aiming to improve treatment outcomes for melioidosis, supported by insights gained from the study and funding from the National Institutes of Health.